MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

The Medicines Company Company Profile (NASDAQ:MDCO)

Consensus Ratings for The Medicines Company (NASDAQ:MDCO) (?)
Ratings Breakdown: 3 Hold Rating(s), 8 Buy Rating(s)
Consensus Rating:Buy (Score: 2.73)
Consensus Price Target: $46.78 (40.56% upside)

Analysts' Ratings History for The Medicines Company (NASDAQ:MDCO)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016Jefferies GroupReiterated RatingBuy$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Chardan CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2016OppenheimerReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/16/2015RBC CapitalBoost Price TargetOutperform$46.00 -> $48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015Piper JaffrayReiterated RatingNeutral$28.00 -> $31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2015GuggenheimBoost Price Target$42.00 -> $45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/31/2015Citigroup Inc.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/6/2015MizuhoUpgradeNeutral -> Buy$28.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/20/2014Credit SuisseUpgradeNeutral -> Outperform$27.00 -> $33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/23/2014Bank of AmericaLower Price TargetBuy -> Neutral$37.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for The Medicines Company (NASDAQ:MDCO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/27/2016        
5/9/2016Q116($0.89)($1.03)$48.96 million$50.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2016Q415($1.54)($0.88)$64.11 million$67.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.88)($0.82)$68.58 million$72.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2015Q215($0.20)($0.65)$122.58 million$90.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115($0.68)($0.02)$138.78 million$126.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2015Q414($0.82)$0.20$191.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/22/2014Q314($0.12)$0.18$188.30 million$172.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2014Q214($0.02)($0.08)$183.75 million$183.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/23/2014Q114($0.07)($0.08)$175.60 million$177.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2014Q413$0.11$0.26$182.60 million$185.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/23/2013Q313$0.24$0.47$173.86 million$173.45 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/24/2013Q2 2013$0.33$0.50$168.70 million$172.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2013Q1 2013($0.26)$0.31$152.63 million$155.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/20/2013Q4 2012$0.28$0.38$146.09 million$159.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/24/2012$0.39$0.40ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2012$0.22$0.46ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/25/2012$0.14$0.27ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/22/2012$0.24$0.52ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/26/2011$0.20$0.17ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/27/2011$0.31$0.21ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/27/2011$0.40$0.45ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/16/2011$0.24$0.30ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for The Medicines Company (NASDAQ:MDCO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.00)($0.76)($0.85)
Q2 20165($1.39)($0.74)($1.10)
Q3 20165($1.40)($0.76)($1.09)
Q4 20165($1.46)($0.77)($1.09)
(Data provided by Zacks Investment Research)
Dividend History for The Medicines Company (NASDAQ:MDCO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for The Medicines Company (NASDAQ:MDCO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/10/2016Christopher T CoxEVPBuy45,985$37.90$1,742,831.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2016Christopher T CoxEVPBuy53,340$37.55$2,002,917.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Melvin K SpigelmanDirectorSell15,000$37.00$555,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Clive MeanwellCEOSell10,000$35.00$350,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016William CrouseDirectorSell15,000$35.15$527,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2016Elizabeth H S WyattDirectorSell15,000$34.07$511,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016Fredric N EshelmanDirectorBuy300,000$33.68$10,104,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2016Armin M KesslerDirectorSell8,100$34.82$282,042.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2015Robert G. SavageDirectorSell5,000$39.34$196,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015Glenn SblendorioCFOSell25,000$42.00$1,050,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Clive MeanwellCEOSell49,998$39.36$1,967,921.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Glenn SblendorioCFOSell114,495$39.75$4,551,176.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Melvin K. SpigelmanDirectorSell20,000$40.50$810,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015William Bernard O'connorSVPSell35,451$40.00$1,418,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Clive MeanwellCEOSell16,667$28.39$473,176.13View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2015Glenn SblendorioCFOSell3,305$32.00$105,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Hiroaki ShigetaDirectorSell7,500$28.99$217,425.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2015Robert G SavageDirectorSell15,000$26.78$401,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/16/2015William Bernard O'connorSVPSell1,281$30.00$38,430.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Clive MeanwellCEOSell16,667$27.58$459,675.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2015Elizabeth H S WyattDirectorSell20,000$28.08$561,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Clive MeanwellCEOSell16,667$30.62$510,343.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Glenn SblendorioCFOSell34,773$30.78$1,070,312.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015William Bernard O'connorSVPSell2,988$28.78$85,994.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014William Bernard O'connorSVPSell2,968$30.31$89,960.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Paul Michael AntinoriVPSell37,883$38.02$1,440,311.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2014William Bernard O'connorSVPSell4,427$39.15$173,317.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/10/2014William Bernard O'connorSVPSell72,384$40.00$2,895,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2014Clive MeanwellCEOSell27,929$38.13$1,064,932.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/3/2014Clive MeanwellCEOSell57,516$38.16$2,194,810.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2013William CrouseDirectorSell12,500$38.00$475,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2013Glenn SblendorioCFOSell8,516$38.50$327,866.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013Clive MeanwellCEOSell10,000$36.58$365,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2013Clive MeanwellCEOSell135,000$36.70$4,954,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2013William Bernard O'connorSVPSell6,354$35.00$222,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2013Paul Michael AntinoriVPSell73,500$34.50$2,535,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Clive MeanwellCEOSell7,500$31.85$238,875.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013Clive MeanwellCEOSell7,500$31.26$234,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2013Paul Michael AntinoriVPSell36,000$33.00$1,188,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Clive MeanwellCEOSell7,500$31.25$234,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013Paul Michael AntinoriVPSell109,973$33.29$3,661,001.17View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2013Armin M KesslerDirectorSell8,750$33.05$289,187.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013Glenn SblendorioCFOSell2,709$37.00$100,233.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2013Paul Michael AntinoriVPSell35,000$34.90$1,221,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2013William Bernard O'connorSVPSell29,654$35.00$1,037,890.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for The Medicines Company (NASDAQ:MDCO)
DateHeadline
06/27/16 05:01 PMThe Medicines Company (NASDAQ:MDCO)'s Company Shares Decreased 10.64% After Low Volatility - Engelwood Daily
06/27/16 05:01 PMLeerink Affirms Medicines Company (MDCO) at 'Outperform'; Carbapenem Component Verified w/ Today's Results - StreetInsider.com
06/27/16 03:06 PMMEDICINES CO /DE Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial Statements and Exh -
06/27/16 10:52 AMMedicines Co's antibiotic succeeds in late-stage trial -
06/27/16 09:27 AMThe Medicines Company Announces Positive Top- Line Results for Phase 3 TANGO 1 Clinical Trial of CARBAVANCE® - Business Wire (press release)
06/27/16 09:27 AMThe Medicines Company (NASDAQ:MDCO) Broker Price Targets For The Coming Week - Fiscal Standard
06/27/16 08:23 AMThe Medicines Company's Carbavance successful in late-stage study in cUTI -
06/27/16 06:31 AMThe Medicines Company Announces Positive Top- Line Results for Phase 3 TANGO 1 Clinical Trial of CARBAVANCE® - [at noodls] - CARBAVANCE (meropenem-vaborbactam) met both FDA and EMA pre-specified primary endpoints in patients with complicated urinary tract infections (cUTI) CARBAVANCE demonstrated statistical superiority over ...
06/25/16 08:54 AMStock Tracing Lower on the Week The Medicines Company (NASDAQ:MDCO) - Engelwood Daily
06/22/16 05:01 PMMedicines Co. (MDCO) Announces Completion of $264M non-Core Cardiovascular Assets Divestiture
06/22/16 05:01 PMThe Medicines Company Completes Divestiture of its Non-Core Cardiovascular Assets to Chiesi
06/22/16 11:00 AMCary's Chiesi USA could pay up to $742M for cardiovascular products -
06/22/16 09:50 AMThe Medicines Company Stock Momentum Hits Weakness - CML News
06/21/16 10:32 AMThe Medicines Co. – Value Analysis (NASDAQ:MDCO) : June 21, 2016 -
06/21/16 09:36 AMThe Medicines Company (NASDAQ:MDCO) Trading Up – Insiders Are Buying and Selling
06/20/16 07:23 AMThe Medicines Co. breached its 50 day moving average in a Bearish Manner : MDCO-US : June 20, 2016 -
06/16/16 05:15 PMLarge Inflow of Money Witnessed in The Medicines Company - Trade Calls
06/15/16 05:04 PMTrading Overview of Two Stocks: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) , The Medicines Company ... - Street Updates
06/14/16 04:52 PMThe Medicines Company initiates phase II study of ABP-700 - Seeking Alpha
06/14/16 08:01 AMThe Medicines Company initiates phase II study of ABP-700 -
06/14/16 06:39 AMThe Medicines Company Announces Initiation of Phase II Study for its Investigational Anesthetic, ABP-700 - [at noodls] - Phase II study to include 75 patients undergoing elective colonoscopies Results anticipated later in 2016 Rapid phase transition following reports of Phase I clinical pharmacology, dosing and safety data ...
06/14/16 06:04 AM7:04 am The Medicines Co initiates Phase II study of ABP-700 in procedural sedation; results anticipated later in 2016 -
06/13/16 04:45 PMThe Medicines Company Announces Participation at ASM MICROBE 2016 to be held June 16 - 20 in Boston
06/13/16 08:00 AMThe Medicines Company Announces Participation at ASM MICROBE 2016 to be held June 16 – 20 in Boston - Business Wire (press release)
06/13/16 06:04 AMThe Medicines Company Announces Participation at ASM MICROBE 2016 to be held June 16 – 20 in Boston - [Business Wire] - The Medicines Company today announced that 11 presentations on its infectious disease programs will be presented at the first annual ASM Microbe 2016 to be held June 16-20 in Boston, MA.
06/10/16 05:21 PMStocks Recommendation Update: Great Basin Scientific, Inc. (NASDAQ:GBSN) , The Medicines Company (NASDAQ ... - Street Updates
06/10/16 03:09 PMMEDICINES CO /DE Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Oblig -
06/09/16 05:20 PMAnalysts Rating Alert: Biogen Inc. (NASDAQ:BIIB) , The Medicines Company (NASDAQ:MDCO) - Street Updates
06/09/16 05:20 PMThe Medicines Company (NASDAQ:MDCO) Fundamental Star Rating Report - CML News
06/08/16 05:29 PMWill The Medicines Company (NASDAQ:MDCO) Surprise Analysts? - Investor Newswire
06/08/16 05:29 PMAnalyst Opinions on: The Medicines Company (NASDAQ:MDCO), Discovery Communications, Inc. (NASDAQ:DISCA) - Beacon Chronicle
06/08/16 07:58 AMAnalysts Review of Stocks: The Medicines Company (NASDAQ:MDCO) , Hologic, Inc. (NASDAQ:HOLX) - Street Updates
06/08/16 07:58 AMHC Stocks in Top Row: The Medicines Company (NASDAQ:MDCO), Catalent Inc (NYSE:CTLT) - share market updates (press release)
06/08/16 07:58 AMHot Stock under Consideration: The Medicines Company (NASDAQ:MDCO) - News Oracle
06/07/16 05:17 PMStock's Earnings Analysis: Kate Spade & Company (NYSE:KATE), The Medicines Company (NASDAQ:MDCO) - Beacon Chronicle
06/07/16 05:17 PMEarnings Estimates Review: The Medicines Company (NASDAQ:MDCO) - News Oracle
06/07/16 07:45 AMThe Medicines Company Prices $350 Million of Convertible Notes - Business Wire (press release)
06/07/16 07:45 AMTHE MEDICINES COMPANY (NASDAQ:MDCO) Financial Condition Compared to S&P 500 - CML News
06/06/16 09:57 PMBRIEF-The Medicines Company prices $350 million of convertible notes - * Says priced its private offering of $350 million in aggregate principal amount of its convertible senior notes due 2023
06/06/16 05:02 PMThe Medicines Company Announces Intention to Offer $350 Million of Convertible Notes
06/06/16 05:02 PMThe Medicines Company to offer $350M in convertible debt
06/06/16 08:49 AMThe Medicines Company Announces Intention to Offer $350 Million of Convertible Notes - Business Wire (press release)
06/06/16 06:48 AMBRIEF-Medicines Co intends to offer $350 mln of convertible notes - * The medicines company announces intention to offer $350 million of convertible notes
06/06/16 06:17 AMMEDICINES CO /DE Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/03/16 07:54 AMTrader's Buzzers: The Medicines Company (NASDAQ:MDCO), Incyte Corporation(NASDAQ:INCY) - NYSE Journal (press release) - Trader's Buzzers: The Medicines Company (NASDAQ:MDCO), Incyte Corporation(NASDAQ:INCY)NYSE Journal (press release)On Thursday, Shares of The Medicines Company (NASDAQ:MDCO), added 0.69% and closed at $37.79 in the last trading session. The last trading range of the stock ranges between $37.08 and $38.02. The Medicines Company (MDCO) has declared the ...
06/02/16 05:27 PMMost Recent Update on Price Moves: The Medicines Company (NASDAQ:MDCO) , Arena Pharmaceuticals, Inc ... - Street Updates - Most Recent Update on Price Moves: The Medicines Company (NASDAQ:MDCO) , Arena Pharmaceuticals, Inc ...Street UpdatesOn 6/1/2016, The Medicines Company (NASDAQ:MDCO) highlighted downward shift of -0.21% or -0.08 points to $37.53. The company traded a volume of 1.09 million shares over average volume of 784.64 thousand shares. Trailing twelve month period, the ...Latest Analyst Reports On The Medicines CompanyRisers & Fallersall 3 news articles »
06/02/16 07:59 AMThe Medicines Company Completes Patient Enrollment for ORION-1 Study of PCSK9si - Business Wire (press release) - The Medicines Company Completes Patient Enrollment for ORION-1 Study of PCSK9siBusiness Wire (press release)PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) has announced the completion of patient enrollment in the ORION-1 study of PCSK9si, its investigational first-in-class RNA interference (RNAi) proprotein convertase ...and more »
06/02/16 06:15 AMThe Medicines Company Completes Patient Enrollment for ORION-1 Study of PCSK9si - [at noodls] - Phase II study enrolled ahead of schedule Randomized 501 patients with high cardiovascular risk and high LDL-C ('bad cholesterol') despite current treatment Aim to demonstrate LDL-C lowering for six months ...
06/01/16 03:47 PMMEDICINES CO /DE Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Byl -
06/01/16 02:40 PMBiogen Says EU Medicines Agency Accepted Its Investigational Alzheimer's Disease Treatment Aducanumab - Biogen Inc. (NASDAQ: BIIB) revealed that aducanumab, its investigational treatment for early Alzheimer's disease (AD), was accepted by the European Medicines Agency's (EMA) PRIority MEdicines (PRIME) program. According to the company, PRIME objective was to bring treatments to patients faster by improving the EMA's support for the development of investigational medicines for diseases without available treatment or in need of better treatment options. Biogen said that with the help of the PRIME program it would gain access to improved support from EMA. This included its ...Full story available on Benzinga.com
About The Medicines Company

The Medicines Company logoThe Medicines Company is a global biopharmaceutical company. The Company's marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Company's products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Company's four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: MDCO
  • CUSIP: 58468810
Key Metrics:
  • Previous Close: $33.28
  • 50 Day Moving Average: $36.07
  • 200 Day Moving Average: $34.49
  • P/E Ratio: N/A
  • P/E Growth: -0.10
  • Market Cap: $2.30B
  • Current Quarter EPS Consensus Estimate: $-4.74 EPS
Additional Links:
The Medicines Company (NASDAQ:MDCO) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha